POTENT NEUTRALIZING MONOCLONAL ANTIBODIES TO HCMV
This technology relates to a Human Cytomegalovirus (HCMV) neutralizing monoclonal antibody that is significantly more potent than the currently marketed alternative Cytogam™. HCMV infection is typically unnoticed in healthy people, but can be life-threatening for the immunocompromised, such as HIV patients, organ …
HIGH-THROUGHPUT ASSAY FOR INHIBITORS OF HIV’S CELL-TO-CELL TRANSMISSION
This technology allows the identification of a new class of antiviral drugs that inhibit the transmission of the Human Immunodeficiency Virus (HIV) through the virological synapse. Although there are several effective treatments for HIV, it continues to remain an incurable condition that …
A VERSATILE IN VIVO RNA-INTERFERENCE DELIVERY PLATFORM
The ability to deliver miRNAs or small interfering RNAs (siRNAs) in vivo has been a major hurdle in harnessing the power of RNA interference. This platform technology employs RNA virus-like vectors to deliver functional small RNAs to any tissue of interest. Depending …
IN VIVO RNAi SCREEN FOR THE IDENTIFICATION OF HOST FACTORS RESTRICTING VIRAL REPLICATION
This technology allows the identification of host restriction factors that limit viral replication in a relevant animal model. Standard siRNA screens are most often conducted in vitro using transformed cell lines and are therefore inherently non-physiological. However, by enabling siRNA delivery through …
USE OF IMATINIB TO TREAT HEPATIC FIBROSIS
There is a huge potential economic impact of establishing a treatment for hepatic fibrosis. Progressive fibrosis of the liver often results in organ failure leading to death or the need for transplantation. These diseases affect hundreds of millions in the United States …
NOVEL LIVE ATTENUATED INFLUENZA VIRUS VACCINES
This technology takes advantage of the species-specific expression of miRNAs to generate live attenuated influenza virus vaccines (LAIVs) alleviating all manufacturing constraints and the necessity of relying on cold-adapted mutants. This technology is enabled by the silent insertion of perfect miRNA target …
MODIFIED VERO CELLS WITH SUPPRESSED INNATE IMMUNE RESPONSES AND ENHANCED VIRUS PRODUCTION
Dr. Chris Basler and colleagues have developed a stable cell line with enhanced virus replication and production efficiency. The Vero 76 cell line (ATCC No. CCL-1587) has been widely used for cell-based research and product development (1, 2, 4). Several characteristics of …
Future of health: LifeMap grabs $5M, partners with Mount Sinai School of Medicine on big data-powered mobile health platform
For better or for worse, we’re living in an era of near constant self-quantification. From wi-fi enabled bathroom scales, to activity monitoring wristbands, to personal DNA sequencing, consumers are gathering more data about their health and wellness than at any time in …
Innovative Public-Private Consortium Established To Define The Triggers Of Inflammatory Bowel Disease
SPRING HOUSE, Pa., May 5, 2014 /PRNewswire/ — Janssen Research & Development, LLC (Janssen) announced today the establishment of a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC), Prometheus Laboratories Inc. (Prometheus), Mayo Clinic, Rochester, Minnesota (Mayo Clinic), Centre Hospitalier Regional Universitaire …
A PROTOCOL FOR GENERATION OF FUNCTIONAL MYELOID-DERIVED SUPPRESSOR CELLS FROM EMBRYONIC STEM CELLS AND HEMATOPOIETIC STEM CELLS
To date, a major limiting factor for the use of MDSCs in certain therapies – in pathological settings where deleterious or excessive immune responses need to be avoided or reduced – is the source of MDSCs. Mount Sinai researchers demonstrated efficient in …